Home › Funds › JOHNSON & JOHNSON › RAPP

JOHNSON & JOHNSON position in RAPP

RAPPORT THERAPEUTICS INC · Health Care

JOHNSON & JOHNSON reported holding 1,784,517 shares of RAPP (RAPPORT THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$60.0M, representing 7.87% of its reported portfolio and ranking #4 among its reported holdings. JOHNSON & JOHNSON has disclosed RAPP holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)1.78M sh
Reported value held$59.96M
Portfolio Weight7.87%
First reportedQ2 2024
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How JOHNSON & JOHNSON's RAPP position evolved

JOHNSON & JOHNSON first disclosed a stake in RAPP in Q2 2024 at 2,498,051 shares (US$58.1M). The position peaked in Q2 2026 at 1,784,517 shares, worth US$74.4M. Across 10 filings, JOHNSON & JOHNSON increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 8 time(s). The most recent filing (Q3 2026) shows 1,784,517 shares valued at US$60.0M. Notable position changes include a 29% trim in Q3 2025 (shares rose 2% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 2.50M $58.10M New
Q3 2024 2.50M $51.16M Hold
Q4 2024 2.50M $44.32M Hold
Q1 2025 2.50M $25.06M Hold
Q2 2025 2.50M $28.55M Hold
Q3 2025 1.78M $53.00M Reduce
Q4 2025 1.78M $54.14M Hold
Q1 2026 1.78M $55.84M Hold
Q2 2026 1.78M $74.36M Hold
Q3 2026 1.78M $59.96M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RAPP and 13F data

RAPP (RAPPORT THERAPEUTICS INC) is a Health Care company. 61 other funds we track also report a position in RAPP — the largest reported positions include TRV GP V, LLC (US$261.7M), ARCH Venture Management, LLC (US$155.4M), Cormorant Asset Management, LP (US$110.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RAPP

All RAPP fund holders →

FAQ

How long has JOHNSON & JOHNSON held RAPP?

JOHNSON & JOHNSON has disclosed RAPP holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

What is JOHNSON & JOHNSON's current position in RAPP?

As of Q3 2026, JOHNSON & JOHNSON holds 1.78M shares of RAPP (RAPPORT THERAPEUTICS INC), valued at $59.96M, representing 7.87% of its reported portfolio and ranking #4.

Has JOHNSON & JOHNSON been buying or selling RAPP?

In the latest 13F filing (Q3 2026), JOHNSON & JOHNSON held unchanged its position in RAPP. The position peaked in Q2 2026 at 1.78M shares.

Which other funds hold RAPP?

Other major institutional holders of RAPP include TRV GP V, LLC, ARCH Venture Management, LLC, Cormorant Asset Management, LP, among 61 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.